Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer

NATerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Colon Cancer
Interventions
DRUG

FOLFOX and bevacizumab

The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.

Trial Locations (5)

10065

Memorial Sloan-Kettering Cancer Center, New York

11570

Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack

07920

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge

Unknown

Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00826800 - Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer | Biotech Hunter | Biotech Hunter